Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities

(E-pub Ahead of Print)

Author(s): Anna Tagka, George I. Lambrou*, Electra Nicolaidou, Evangelia Nakou, Michael Makris, Alexandros Stratigos, Alexandra Katsarou

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents)

Become EABM
Become Reviewer


Background: Chronic Spontaneous Urticaria (CSU) is a disease presenting typical wheals characterized by itching, angioedema or both. Although CU is by appearance a relatively “simple” disease, yet it has a devastating effect on those suffering due to its immense social implications.

Aim: The aim of the present study was to investigate the effect of omalizumab in the treatment of CSU. In particular, gender, drug co-administration and co-morbidities were taken into account.

Materials and Method: 108 patients (25 Males/83 Females) admitted to our department were diagnosed with CSU and were treated for a total of 30 months. CSU was estimated on score basis, which was used in order to define disease severity. The mean total CSU score and the mean CSU score of the first trimester as well as first semester were calculated. Patients were treated with omalizumab and in several cases with co-administration of dapsone, cyclosporine and anti-histamines. Results: Females manifested significantly higher scores as compared to males. Further on, patients that relapsed manifested significantly higher scores during the whole time course, as well as at the end of the first semester.

Conclusions: Females are more prone to CSU. Although CSU score in patients with remission, relapse and poor response manifested no significant difference at diagnosis, relapsed patients manifested higher CSU score at the first semester. Therefore, first semester of treatment is probably critical for the final patient outcome. Further studies are necessary in order to understand the mechanisms of CSU for better treatment and prognosis.

Keywords: Chronic Urticaria, Chronic Spontaneous Urticaria, Omalizumab, Dapsone, Cyclosporine, Relapse, Prevalence

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871523019666200203123734
Price: $95

Article Metrics

PDF: 5